AdaptHealth (AHCO) Q4 2025: Capitated Contract Adds 5%–6% Revenue Growth, Reshaping Home Medical Model
AdaptHealth’s Q4 capped a pivotal year, with the launch of the industry’s largest capitated contract transforming both growth and operational complexity. Margin cadence and capital allocation signal a business in transition, with technology pilots and divestitures sharpening focus on core strengths. The company’s 2026 outlook leans heavily on execution of the new contract, with upside from operational leverage and risk from payer mix in diabetes.
Summary
- Capitated Model Expansion: New contract ramps up, diversifying revenue streams and driving operational overhaul.
- Operational Discipline: Standardization and technology pilots improve patient setup times and retention, supporting margin recovery.
- Execution Watchpoint: Diabetes segment stability and payer mix shifts remain key variables for 2026 performance.
Performance Analysis
AdaptHealth’s Q4 results reflect a business in strategic transition, with organic revenue growth of 1.7% both for the quarter and full year, even as reported revenue declined due to non-core asset divestitures. The standout driver is the successful onboarding of the industry’s largest capitated contract, which is expected to add 5%–6% to 2026 revenue—providing a new, recurring stream that changes both growth and risk profile. Patient census hit all-time records across sleep, respiratory, and wellness at home, with new starts in sleep up 6% and respiratory up 4%–5%.
Profitability dynamics were shaped by a $14.5 million legal settlement and $10 million in accelerated costs tied to the capitated contract launch, temporarily pressuring adjusted EBITDA margins. Excluding these, underlying margin discipline remains evident, with 2025’s adjusted EBITDA margin at 19%. The diabetes segment, while stabilized on patient retention, continues to face reimbursement headwinds from a payer mix shift toward government payers, offsetting otherwise strong pump growth. Free cash flow exceeded guidance, supporting both debt reduction and targeted acquisitions, including a Hawaii provider to bolster the capitated footprint.
- Segment Divergence: Sleep and respiratory segments delivered record census and new starts, while diabetes lagged on revenue due to payer mix.
- Margin Volatility: One-time legal and onboarding costs compressed Q4 margins, but normalized margin expansion is expected as contract ramps.
- Capital Discipline: $250 million in debt reduction and selective M&A reflect a sharpened focus on core businesses and balance sheet health.
Overall, the quarter marks a business shifting from portfolio cleanup to operational scale, with execution on the capitated contract and margin recovery as central themes for 2026.
Executive Commentary
"We closed the largest capitated contract in the history of the industry, and we honed our portfolio by disposing of non-core assets, using those proceeds in our strong free cash flow to pay down debt and strengthen our balance sheet. The work we completed last year not only positions us for accelerated growth and improved financial performance in 2026 and beyond, but is essential to achieving our aspiration to become the most trusted and reliable partner in home medical equipment and services."
Suzanne Foster, Chief Executive Officer
"We decreased interest expense by approximately $21 million versus the prior year, and the recent credit upgrades from both S&P and Moody's in the fourth quarter reflect the progress we've made as an organization. Our priorities remain investing to accelerate organic growth, debt reduction, and selective tuck-in acquisitions that expand our geographic footprint and increase patient access."
Jason Clements, Chief Financial Officer
Strategic Positioning
1. Capitated Contract Scale and Execution
The largest-ever capitated contract in home medical equipment (HME, fixed per-patient payment model) is now live, with over 10 million patients and 1,200 dedicated staff across 30 locations. Early onboarding exceeded expectations, with smooth transitions in the Mid-Atlantic and infrastructure investments supporting upcoming rollouts. This contract is expected to deliver 5%–6% revenue growth in 2026, shifting the business toward recurring, contract-based revenue and raising the bar for operational complexity and service delivery.
2. Operational Standardization and Technology Leverage
Centralized order intake and workflow standardization have driven improved patient setup times (e.g., sleep referral-to-setup fell from 23 days to 9 days over a year), higher order conversion, and best-in-class clinical adherence. AI pilots for order intake and self-scheduling are reducing processing and phone time, with broader rollouts planned. These operational gains underpin management’s confidence in margin recovery as the year progresses.
3. Portfolio Rationalization and Capital Allocation
Divestitures of non-core assets (notably in wellness at home) and targeted acquisitions (e.g., Hawaii HME provider) reflect a sharpened focus on core, scalable businesses. Capital allocation priorities remain: organic growth investment, debt paydown, and tuck-in M&A, all funded through free cash flow. This disciplined approach is credited with S&P and Moody’s credit upgrades and a lower interest expense run rate.
4. Segment-Specific Growth and Payer Mix Risks
Sleep and respiratory segments are positioned for above-average growth, with record census and new starts. Diabetes health, however, faces a challenging payer mix with reimbursement pressure, though retention has improved due to operational integration. Management is investing in sales force expansion to drive new starts but is guiding to flat segment performance until trends prove out.
5. Regulatory and Industry Tailwinds
CMS’s exclusion of core sleep and respiratory products from the next round of competitive bidding provides reimbursement stability, a material positive for long-term planning. Management believes operational scale and compliance investments give AdaptHealth an advantage as regulatory and payer requirements intensify.
Key Considerations
The strategic context for Q4 is a business pivoting from cleanup to scalable growth, with the capitated contract as both an opportunity and an execution test.
Key Considerations:
- Contract Ramp Dynamics: Revenue and margin cadence in 2026 will be shaped by the onboarding pace and cost absorption of the new capitated contract.
- Technology ROI Realization: AI and digital engagement pilots are not yet material but embedded in long-term margin guidance.
- Diabetes Segment Sensitivity: Reimbursement pressure from payer mix shifts could offset operational gains if not reversed by new start growth.
- Capital Allocation Flexibility: Free cash flow strength enables both debt reduction and opportunistic M&A, but future acquisitions must deliver strategic fit and returns.
- Competitive Moat: Scale, compliance, and technology investments may widen the gap versus smaller HME peers as regulatory demands increase.
Risks
The largest risk is execution on the complex, multi-state rollout of the capitated contract, where onboarding delays or service failures could impair growth and margin targets. Diabetes segment remains exposed to further reimbursement declines if payer mix continues to shift. One-time legal and onboarding costs highlight exposure to legacy compliance and transition risk, and any disruption could slow credit improvement or capital deployment flexibility. Industry-wide regulatory or payer changes could also impact future reimbursement rates.
Forward Outlook
For Q1 2026, AdaptHealth guided to:
- Revenue growth of 2%–3% year over year
- Adjusted EBITDA margin of approximately 16%, with margin expected to rise through the year as contract revenue ramps
For full-year 2026, management maintained guidance:
- Net revenue of $3.44–$3.51 billion (6%–8% growth)
- Adjusted EBITDA of $680–$730 million (margin improvement to ~20.3%)
- Free cash flow of $175–$225 million
Management highlighted:
- Capitated contract to contribute 5%–6% of revenue growth, with incremental margin leverage expected in H2 2026
- Sleep and respiratory segments to outpace overall growth, while diabetes and wellness at home remain flat until new initiatives prove out
Takeaways
AdaptHealth enters 2026 with a fundamentally reshaped business model, operational foundation, and risk profile.
- Capitated Contract as Growth Engine: Successful onboarding and scale-up are central to both revenue and margin expansion, but increase operational and compliance complexity.
- Margin and Cash Flow Recovery: One-time costs are expected to abate, with normalized operating leverage from technology and standardization supporting improved profitability.
- Segment Watchpoints: Diabetes health requires close monitoring for payer mix stabilization and new start acceleration; sleep and respiratory are well-positioned for outsized growth.
Conclusion
AdaptHealth’s Q4 and 2025 results mark a transition from portfolio cleanup to scalable, contract-driven growth. The successful launch of the largest-ever capitated contract sets up a new era of recurring revenue, but places a premium on flawless execution and operational maturity. Investors should watch for margin expansion, contract ramp progress, and diabetes segment trends as the key determinants of value creation in 2026.
Industry Read-Through
AdaptHealth’s pivot to large-scale capitated contracts signals accelerating movement toward value-based care models in home medical equipment, with payers seeking partners capable of managing both cost and outcomes at scale. The operational and technology investments required to execute these contracts may widen the gap between national leaders and smaller providers, particularly as regulatory complexity and documentation requirements increase. Stability in reimbursement for core products and the exclusion from CMS competitive bidding provide near-term tailwinds, but the diabetes segment’s payer mix challenges may foreshadow broader industry shifts as government payers gain share. Other HME and post-acute care providers should monitor AdaptHealth’s execution for signals on the feasibility and pitfalls of scaling capitated models.